Oleĭnik E K, Oleĭnik V M, Bakhlaev I E, Ageenko A I
Institute of Biology of the Karelian Research Center, Russian Academy of Sciences, Republican Oncological Dispensary, Petrozavodsk.
Vopr Onkol. 2001;47(4):436-9.
The expression of surface markers of blood lymphocytes was studied in 32 lung cancer patients. Tumor process involved enhanced expression of the activation markers CD25, CD71 and HLA-DR as well as differentiation antigens CD4, CD8, CD22 and CD16. The expression of the markers was higher than in control, irrespective of stage, localization and histological pattern of tumor. It is suggested that increased expression of surface markers should be accounted for by tumor-induced suppression of the immune system in lung cancer.
对32例肺癌患者血液淋巴细胞的表面标志物表达进行了研究。肿瘤进程涉及激活标志物CD25、CD71和HLA-DR以及分化抗原CD4、CD8、CD22和CD16的表达增强。无论肿瘤的分期、定位和组织学类型如何，这些标志物的表达均高于对照组。提示肺癌患者表面标志物表达增加应归因于肿瘤诱导的免疫系统抑制。
